Top four reasons the Democrats are failing‘Vanity Fair’ Faces Major Backlash Over Cormac McCarthy Scoop
W hen Kenyan police arrived in Haiti as part of a U.N.-backed mission earlier this year to tackle gang violence, hopes were high. Coordinated gang attacks on prisons, police stations and the main international airport had crippled the country’s capital and forced the prime minister to resign, plunging Haiti into an unprecedented crisis. But the crisis has only deepened since the international policing contingent arrived. The main international airport closed for the second time this year after gangs opened fire on commercial flights in mid-November, striking a flight attendant. Gunmen also are attacking once-peaceful communities to try and seize control of the entire capital, taking advantage of political infighting that led to the abrupt dismissal of the prime minister earlier this month. Now, a new prime minister is tasked with turning around a nation that sees no escape from its troubles as Haitians wonder: How did the country reach this point? Bloody coups, brutal dictatorships and gangs created by Haiti’s political and economic elite have long defined the country’s history, but experts say the current crisis is the worst they’ve seen. “I’m very bleak about the future,” said Robert Fatton, a Haitian politics expert at the University of Virginia. “The whole situation is really collapsing.” You Might Be Interested In HAITI-Three killed, several wounded during pre-Carnival celebration REGIONAL – CARICOM calls for political parties to act responsibly in Haiti HAITI – Protests choke communities in Haiti as aid, supplies dwindle The government is anemic, the U.N.-backed mission that supports Haiti’s understaffed police department lacks funding and personnel, and gangs now control 85% of the capital. Then, on Wednesday, another blow. Doctors Without Borders announced it was suspending critical care in Port-au-Prince as it accused police of targeting its staff and patients, including threats of rape and death. It’s the first time the aid group has stopped working with new patients since it began operating in Haiti more than 30 years ago. “Every day that we cannot resume activities is a tragedy, as we are one of the few providers of a wide range of medical services that have remained open during this extremely difficult year,” said Christophe Garnier, mission director in Haiti. Lionel Lazarre, deputy spokesman for Haiti’s National Police, did not return messages for comment. Neither did officials with Kenya’s mission when asked about the surge in gang violence. In a recent statement, the Kenyan-led mission said it was “cognizant of the road ahead that is fraught with challenges.” But it noted that ongoing joint patrols and operations have secured certain communities and forced gangs to change the way they operate. Andre Francois Giroux, Canada’s ambassador to Haiti, told The Associated Press on Saturday that his country and others have been trying to bolster the Kenyan-led mission. “They’ve done miracles, I think, considering all the challenges that we’ve been facing,” he said. “What we have to keep in mind is that it’s still very much in deployment mode,” Giroux said. “There are not even 400 on the ground right now.” A spokesman for Haiti’s new prime minister, Alix Didier Fils-Aime, did not return messages for comment. In a statement Thursday, his administration said authorities were strengthening security along the capital’s main roads and had formed a special security council. “The prime minister renews his commitment to find lasting solutions to current problems,” it said. The statement was issued just days after gangs launched a pre-dawn attack Tuesday around an upper-class community in Haiti’s capital, forcing residents armed with machetes and guns to fight side-by-side with police to repel gunmen. At least 28 gang members were killed, but not before some reached an area near an upscale hotel long considered safe. “It tells you that there is no functioning authority in Haiti,” Fatton said. A main concern in the ongoing crisis is the temporary closure of the main international airport in Port-au-Prince. It means critical aid is not reaching those who need it the most in a country where nearly 6,000 people are starving and nearly half of the more than 11 million inhabitants are experiencing crisis levels of hunger or worse. Gang violence also has left more than 700,000 people homeless in recent years. “We are deeply concerned about the isolation of Port-au-Prince from the rest of Haiti and the world,” said Laurent Uwumuremyi, Mercy Corps’ country director for Haiti. The aid group helps people including more than 15,000 living in makeshift shelters, but persistent gang violence has prevented workers from reaching a growing number of them in the capital and beyond. Basic goods also are dwindling as the suspension of flights has delayed imports of critical supplies. “Before, there were some neighborhoods in Port-au-Prince that we considered safe that the gangs had never reached, but now they are threatening to take over the control of the entire capital,” Uwumuremyi said. At least 150 people were reported killed in the capital and 20,000 forced to flee their homes in the second week of November alone. Overall, more than 4,500 people were reported killed in Haiti so far this year, the U.N. said. Jimmy Cherizier, a former elite police officer who became a gang leader known as Barbecue, warned that a gang coalition known as Viv Ansanm will keep attacking as they demand the resignation of a transitional presidential council tasked with leading the country along with the new prime minister. The council also is supposed to organize general elections for the first time in nearly a decade so voters can choose a president, a position left empty since President Jovenel Moise was killed at his private residence in July 2021. The U.S. and other countries pushed for a U.N. peacekeeping mission in Haiti at a U.N. Security Council meeting this week. Only about 400 officers from Kenya have arrived, along with a handful of police and soldiers from other countries — way short of the 2,500 personnel slated for the mission. “This is not just another wave of insecurity; it is a dramatic escalation that shows no signs of abating,” Miroslav Jen─ìa, U.N. assistant secretary general for Europe, Central Asia and the Americas, said Wednesday at the meeting. But Russia and China oppose a U.N. peacekeeping mission, leaving many to wonder what other options are left for Haiti. Giroux, the Canadian ambassador, said his country supports a peacekeeping operation “when the time is right.” “Everybody is looking at a peacekeeping mission as a silver bullet,” he said, adding that even if that were to happen, it wouldn’t be able to deploy for another six to 12 months. “We need to be realistic.” Giroux said he is hopeful that some 600 Kenyans will arrive in Haiti in upcoming weeks, but added that “none of this matters if the political elite doesn’t get its act together.” The nine-member transitional presidential council has been marred by accusations of corruption and infighting and was criticized for firing the previous prime minister. “I’m at a loss for any short-term solution for Haiti, let alone any long-term solutions,” Fatton said. “The gangs have seen that they shouldn’t be afraid of the Kenyan mission.” He said one option may be for the government to negotiate with the gangs. “At the moment, it is perceived as utterly unacceptable,” he said. “But if the situation deteriorates even more, what else are you left with?” SOURCE: The Associated PressPETALING JAYA: The much-awaited results for the Putra Brand Awards (PBA) and Putra Aria Brand Awards (PABA) for 2024 have been finalised. Billed as the “People’s Choice Awards”, the awards organising chairman and senior adviser of the Association of Accredited Advertising Agents Malaysia (4As) Datuk Johnny Mun told StarBiz the board of governors met late October to endorse the results. “The research was conducted by Ipsos, which is a global leader in market research. We have a record number of participants in the research numbering over 20,000 unique respondents with well over 65,000 responses. “This makes the PABA and PBA the most robust research event in the country and probably in Asia covering over 60 digital media platforms. “There are some surprises in the awards this year with some perennial winners being replaced by newcomers,” he added. Mun said the survey covers multiple categories, allowing consumers to voice their opinions on their favourite brands in areas ranging from food and beverage to technology and personal care. He reiterated that this comprehensive approach provides a holistic view of consumer preferences and highlights brands that have successfully established strong connections with their audience. He said the award nights for PABA are on Jan 16 and for PBA on Jan 17. Mun said the venue has shifted back to the iconic Majestic Hotel, Kuala Lumpur, to match the pomp and importance of the events. Mun is also calling marketers to buy their tables to celebrate the 15th instalment of the PBA and the third instalment of PABA to avoid disappointment. He added that for PABA, there are over 150 awards and for PBA over 160 awards. Both awards are organised by the 4As in collaboration with Star Media Group Bhd . The event is supported by the Malaysian Advertisers Association, Media Specialists Association and Malaysian Digital Association and is endorsed as Brand Champion Partner by Malaysia External Trade Development Corp or Matrade. The Star is the official news partner for the awards. The highlight for the PBA show would be the four special awards similar to last year. They are the Putra Most Enterprising Brand of the Year, Putra Malaysian Marketer of the Year, Putra Brand Personality Award and Putra Brand of the Year. There would also be the Putra Hall of Fame award, an accolade introduced in 2019 for brands that have won their respective categories for over 10 successive years. The Putra Most Enterprising Brand of the Year award reflects outstanding achievements in developing a brand that has made strong inroads into the international market via product or service innovation; is committed to comprehensive marketing and communications programmes and demonstrates a strong corporate social responsibility (CSR) commitment. The Putra Brand Personality Award celebrates an outstanding individual with creativity, perseverance and persuasion that have made significant contributions to nation building. The Putra Malaysian Marketer of the Year accolade recognises a company, team or individual exhibiting overall excellence in marketing, innovation and creativity in brand building, while challenging conventional strategies in the product sector. Lastly, the Putra Brand of the Year award is presented to the brand that best exemplifies continuous product innovation, commitment to brand building via communication and exhibits a strong sense of CSR.SAN RAMON, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, today announced financial results for its fiscal fourth quarter and full year ended October 31, 2024. Fourth quarter 2024 revenue of $1,018.4 million, up 10%, or up 7% organically. Fiscal year 2024 revenue of $3.9 billion, up 8%, or up 8% organically. Fourth quarter 2024 GAAP diluted earnings per share (EPS) of $0.58, up 38%. Fiscal 2024 GAAP diluted EPS of $1.96, up 33%. Fourth quarter 2024 non-GAAP diluted EPS of $1.04, up 19%. Fiscal 2024 non-GAAP diluted EPS of $3.69, up 15%. See "Reconciliation of Selected GAAP Results to Non-GAAP Results" below. Commenting on the results, Al White, Cooper's President and CEO said, "Fiscal 2024 was a great year for Cooper having achieved record consolidated revenues, including record CooperVision revenues, record CooperSurgical revenues and record non-GAAP EPS. We look forward to continued success in fiscal 2025 and thank all of our employees for driving these results." Fourth Quarter Operating Results Revenue of $1,018.4 million, up 10% from last year’s fourth quarter, up 9% in constant currency, up 7% organically. Gross margin of 67% compared with 65% in last year’s fourth quarter driven by price and efficiency gains. On a non-GAAP basis, gross margin was similar to last year at 67%. Operating margin of 19% compared with 15% in last year’s fourth quarter driven by SG&A expense leverage and stronger gross margins. On a non-GAAP basis, operating margin was 26%, up from 24% last year. Interest expense of $27.0 million compared with $26.3 million in last year's fourth quarter. On a non-GAAP basis, interest expense was $25.6 million, down from $26.4 million. Cash provided by operations of $268.1 million offset by capital expenditures of $139.9 million resulted in free cash flow of $128.2 million. Fourth Quarter CooperVision (CVI) Revenue Revenue of $676.4 million, up 9% from last year’s fourth quarter, up 8% in constant currency, up 8% organically. Revenue by category: Revenue by geography: Fourth Quarter CooperSurgical (CSI) Revenue Revenue of $342.0 million, up 12% from last year's fourth quarter, up 12% in constant currency, up 5% organically. Revenue by category: Fiscal Year 2024 Operating Results Revenue of $3,895.4 million, up 8% from fiscal 2023, up 9% in constant currency, up 8% organically. CVI revenue of $2,609.4 million, up 8% from fiscal 2023, up 8% in constant currency, up 9% organically, and CSI revenue $1,286.0 million, up 10% from fiscal 2023, up 11% in constant currency, up 5% organically. Gross margin of 67% compared with 66% in fiscal 2023. Non-GAAP gross margin was 67% compared with 66% in fiscal 2023. Operating margin of 18% compared with 15% in fiscal 2023. Non-GAAP operating margin was 25% compared with 24% in fiscal 2023. Cash provided by operations of $709.3 million offset by capital expenditures of $421.2 million resulted in free cash flow of $288.1 million. Fiscal Year 2025 Financial Guidance The Company initiated its fiscal year 2025 financial guidance. Details are summarized as follows: Fiscal 2025 total revenue of $4,080 - $4,158 million (organic growth of 6% to 8%) CVI revenue of $2,733 - $2,786 million (organic growth of 6.5% to 8.5%) CSI revenue of $1,347 - $1,372 million (organic growth of 4% to 6%) Fiscal 2025 non-GAAP diluted earnings per share of $3.92 - $4.02 Non-GAAP diluted earnings per share guidance excludes amortization and impairment of intangible assets, and certain income or gains and charges or expenses including acquisition and integration costs which we may incur as part of our continuing operations. With respect to the Company’s guidance expectations, the Company has not reconciled non-GAAP diluted earnings per share guidance to GAAP diluted earnings per share due to the inherent difficulty in forecasting acquisition-related, integration and restructuring charges and expenses, which are reconciling items between the non-GAAP and GAAP measures. Due to the unknown effect, timing and potential significance of such charges and expenses that impact GAAP diluted earnings per share, the Company is not able to provide such guidance. Reconciliation of Selected GAAP Results to Non-GAAP Results To supplement our financial results and guidance presented on a GAAP basis, we provide non-GAAP measures such as non-GAAP gross margin, non-GAAP operating margin, non-GAAP diluted earnings per share, as well as constant currency and organic revenue growth because we believe they are helpful for the investors to understand our consolidated operating results. Management uses supplemental non-GAAP financial measures internally to understand, manage and evaluate our business, to make operating decisions, and to plan and forecast for future periods. The non-GAAP measures exclude costs which we generally would not have otherwise incurred in the periods presented as a part of our continuing operations. We provide further details of the non-GAAP adjustments made to arrive at our non-GAAP measures in the GAAP to non-GAAP reconciliations below. Our non-GAAP financial results and guidance are not meant to be considered in isolation or as a substitute for comparable GAAP measures and should be read only in conjunction with our consolidated financial statements prepared in accordance with GAAP. To present constant currency revenue growth, current period revenue for entities reporting in currencies other than the United States dollar are converted into United States dollars at the average foreign exchange rates for the corresponding period in the prior year. To present organic revenue growth, we excluded the effect of foreign currency fluctuations and the impact of any acquisitions, divestitures and discontinuations that occurred in the comparable period. We define the non-GAAP measure of free cash flow as cash provided by operating activities less capital expenditures. We believe free cash flow is useful for investors as an additional measure of liquidity because it represents cash that is available to grow the business, make strategic acquisitions, repay debt, or buyback common stock. Management uses free cash flow internally to understand, manage, make operating decisions and evaluate our business. In addition, we use free cash flow to help plan and forecast future periods. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. EPS, amounts and percentages may not sum or recalculate due to rounding. (1) Charges include the direct effects of acquisition accounting, such as amortization of inventory fair value step-up, professional services fees, regulatory fees and changes in fair value of contingent considerations, and items related to integrating acquired businesses, such as redundant personnel costs for transitional employees, other acquired employee related costs, and integration-related professional services, manufacturing integration costs, legal entity rationalization and other integration-related activities. The acquisition and integration-related charges in fiscal 2024 were primarily related to the Cook Medical acquisition and integration expenses. The acquisition and integration-related charges in fiscal 2023 were primarily related to the Generate acquisition and integration expenses. Charges included $2.9 million and $8.4 million related to redundant personnel costs for transitional employees, $0.7 million and $4.5 million of professional services fees, $1.4 million and $1.4 million of manufacturing integration costs, $1.5 million and 1.5 million of inventory fair value step-up amortization, and $0.7 million and $4.1 million of other acquisition and integration-related activities in the three and twelve months ended October 31, 2024, respectively. The twelve months ended October 31, 2024 also included $0.7 million regulatory fees. Charges included $7.5 million and $21.9 million related to redundant personnel costs for transitional employees, $6.5 million and $16.2 million of professional services fees, $2.9 million and $6.5 million of manufacturing integration costs, $3.1 million and $5.0 million of legal entity rationalization costs, $0.9 million and $2.7 million regulatory fees, and $0.6 million and $5.0 million in other acquisition and integration-related activities, in the three and twelve months ended October 31, 2023, respectively. (2) Charges include costs related to product line exits such as inventory write-offs, site closure costs, contract termination costs and specifically-identified long-lived asset write-offs. Charges included $2.3 million of write-offs of long-lived assets and $1.7 million of other costs related to product line exits in the twelve months October 31, 2024. No charge related to product line exits was incurred in the three months ended October 31, 2024. Charges included $3.4 million and $7.9 million of site closure costs related to the exit of the lens care business, $0.4 million and $1.1 million of other costs related to product line exits in the three and twelve months ended October 31, 2023, respectively. The fourth quarter of fiscal 2023 also included $9.8 million of intangible assets impairment charge associated with the discontinuation of certain products. (3) Charges represent incremental costs of complying with the new European Union (E.U.) medical device regulations for previously registered products and primarily include charges for contractors supporting the project and other direct third-party expenses. We consider these costs to be limited to a specific time period. (4) Charges represent the costs associated with initiatives to increase efficiencies across the organization and optimize our overall cost structure, including changes to our IT infrastructure and operations, employee severance costs, legal entity and other business reorganizations, write-offs or impairments of certain long-lived assets associated with the business optimization activities. Charges included $1.5 million and $10.6 million of employee severance costs, $1.0 million and $4.1 million related to changes to our IT infrastructure and operation, and $0.4 million and $2.9 million of legal entity and other business reorganizations costs, in the three and twelve months ended October 31, 2024, respectively. The twelve months ended October 31, 2024 also included $0.7 million of other optimization costs. Charges included $1.4 million and $11.3 million of employee severance costs, $1.4 million and $1.9 million of legal entity and other business reorganizations costs, and $0.3 million and $5.9 million related to changes to our IT infrastructure and operations, partially offset by $0.2 million and $0.4 million of other items in the three and twelve months ended October 31, 2023, respectively. (5) Amount represents an accrual for probable payment of a termination fee in connection with an asset purchase agreement in the second quarter of 2023, which was paid in August 2023. (6) Amount represents the release the contingent consideration liability associated with SightGlass Vision's regulatory approval milestone in the first quarter of 2023. (7) Charges include certain business disruptions from natural causes, litigation matters and other items that are not part of ordinary operations. The adjustments to arrive at non-GAAP net income also include gains and losses on minority interest investments and accretion of interest attributable to acquisition installment payables. Charges included $1.5 million and $5.9 million of gains and losses on minority interest investments, $1.4 million and $5.5 million of accretion of interest attributable to acquisition installments payable, $0.6 million and $1.5 million related to legal matters in the three and twelve months ended October 31, 2024, respectively. Charges included $1.6 million and $6.3 million of gains and losses on minority interest investments, and $1.3 million and $4.6 million related to legal matters in the three and twelve months ended October 31, 2023, respectively. The twelve months ended October 31, 2023 also included $1.1 million of other items. (8) In fiscal 2021, the Company transferred its CooperVision intellectual property and goodwill to its UK subsidiary. As a result, we recorded a deferred tax asset equal to approximately $2.0 billion as a one-time tax benefit in accordance with U.S. GAAP in fiscal 2021 as subsequently adjusted for changes in UK tax law. The non-GAAP adjustments reflect the ongoing net deferred tax benefit from tax amortization each period under UK tax law. Audio Webcast and Conference Call The Company will host an audio webcast today for the public, investors, analysts and news media to discuss its fourth quarter results and current corporate developments. The audio webcast will be broadcast live on CooperCompanies' website, www.investor.coopercos.com , at approximately 5:00 PM ET. It will also be available for replay on CooperCompanies' website, www.investor.coopercos.com . Alternatively, you can dial in to the conference call at 800-715-9871; conference ID 2026064. About CooperCompanies CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on improving lives one person at a time. The Company operates through two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, improving the vision of millions of people every day. CooperSurgical is a leading fertility and women's health company dedicated to assisting women, babies and families at the healthcare moments that matter most. Headquartered in San Ramon, CA, CooperCompanies ("Cooper") has a workforce of more than 16,000 with products sold in over 130 countries. For more information, please visit www.coopercos.com . Forward-Looking Statements This earnings release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Statements relating to guidance, plans, prospects, goals, strategies, future actions, events or performance and other statements of which are other than statements of historical fact, including our fiscal year 2025 financial guidance are forward looking. In addition, all statements regarding anticipated growth in our revenues, anticipated effects of any product recalls, anticipated market conditions, planned product launches, restructuring or business transition expectations, regulatory plans, and expected results of operations and integration of any acquisition are forward-looking. To identify these statements look for words like "believes," "outlook," "probable," "expects," "may," "will," "should," "could," "seeks," "intends," "plans," "estimates" or "anticipates" and similar words or phrases. Forward-looking statements necessarily depend on assumptions, data or methods that may be incorrect or imprecise and are subject to risks and uncertainties. Among the factors that could cause our actual results and future actions to differ materially from those described in forward-looking statements are: adverse changes in the global or regional general business, political and economic conditions including the impact of continuing uncertainty and instability of certain countries, man-made or natural disasters and pandemic conditions, that could adversely affect our global markets, and the potential adverse economic impact and related uncertainty caused by these items; the impact of international conflicts and the global response to international conflicts on the global and local economy, financial markets, energy markets, currency rates and our ability to supply product to, or through, affected countries; our substantial and expanding international operations and the challenges of managing an organization spread throughout multiple countries and complying with a variety of legal, compliance and regulatory requirements; foreign currency exchange rate and interest rate fluctuations including the risk of fluctuations in the value of foreign currencies or interest rates that would decrease our net sales and earnings; our existing and future variable rate indebtedness and associated interest expense is impacted by rate increases, which could adversely affect our financial health or limit our ability to borrow additional funds; changes in tax laws, examinations by tax authorities, and changes in our geographic composition of income; acquisition-related adverse effects including the failure to successfully achieve the anticipated net sales, margins and earnings benefits of acquisitions, integration delays or costs and the requirement to record significant adjustments to the preliminary fair value of assets acquired and liabilities assumed within the measurement period, required regulatory approvals for an acquisition not being obtained or being delayed or subject to conditions that are not anticipated, adverse impacts of changes to accounting controls and reporting procedures, contingent liabilities or indemnification obligations, increased leverage and lack of access to available financing (including financing for the acquisition or refinancing of debt owed by us on a timely basis and on reasonable terms); compliance costs and potential liability in connection with U.S. and foreign laws and health care regulations pertaining to privacy and security of personal information such as the Health Insurance Portability and Accountability Act of 1996 (HIPAA) and the California Consumer Privacy Act (CCPA) in the U.S. and the General Data Protection Regulation (GDPR) requirements in Europe, including but not limited to those resulting from data security breaches; a major disruption in the operations of our manufacturing, accounting and financial reporting, research and development, distribution facilities or raw material supply chain due to challenges associated with integration of acquisitions, man-made or natural disasters, pandemic conditions, cybersecurity incidents or other causes; a major disruption in the operations of our manufacturing, accounting and financial reporting, research and development or distribution facilities due to the failure to perform by third-party vendors, including cloud computing providers or other technological problems, including any related to our information systems maintenance, enhancements or new system deployments, integrations or upgrades; a successful cybersecurity attack which could interrupt or disrupt our information technology systems, or those of our third-party service providers, or cause the loss of confidential or protected data; market consolidation of large customers globally through mergers or acquisitions resulting in a larger proportion or concentration of our business being derived from fewer customers; disruptions in supplies of raw materials, particularly components used to manufacture our silicone hydrogel lenses; new U.S. and foreign government laws and regulations, and changes in existing laws, regulations and enforcement guidance, which affect areas of our operations including, but not limited to, those affecting the health care industry, including the contact lens industry specifically and the medical device or pharmaceutical industries generally, including but not limited to the EU Medical Devices Regulation (MDR), and the EU In Vitro Diagnostic Medical Devices Regulation (IVDR); legal costs, insurance expenses, settlement costs and the risk of an adverse decision, prohibitive injunction or settlement related to product liability, patent infringement, contractual disputes, or other litigation; limitations on sales following product introductions due to poor market acceptance; new competitors, product innovations or technologies, including but not limited to, technological advances by competitors, new products and patents attained by competitors, and competitors' expansion through acquisitions; reduced sales, loss of customers, reputational harm and costs and expenses, including from claims and litigation related to product recalls and warning letters; failure to receive, or delays in receiving, regulatory approvals or certifications for products; failure of our customers and end users to obtain adequate coverage and reimbursement from third-party payers for our products and services; the requirement to provide for a significant liability or to write off, or accelerate depreciation on, a significant asset, including goodwill, other intangible assets and idle manufacturing facilities and equipment; the success of our research and development activities and other start-up projects; dilution to earnings per share from acquisitions or issuing stock; impact and costs incurred from changes in accounting standards and policies; risks related to environmental laws and requirements applicable to our facilities, products or manufacturing processes, including evolving regulations regarding the use of hazardous substances or chemicals in our products; risks related to environmental, social and corporate governance (ESG) issues, including those related to regulatory and disclosure requirements, climate change and sustainability; and other events described in our Securities and Exchange Commission filings, including the “Business”, “Risk Factors” and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections in the Company’s Annual Report on Form 10-K for the fiscal year ended October 31, 2024, as such Risk Factors may be updated in annual and quarterly filings. We caution investors that forward-looking statements reflect our analysis only on their stated date. We disclaim any intent to update them except as required by law. Contact: Kim Duncan Vice President, Investor Relations and Risk Management 925-460-3663 ir@cooperco.com THE COOPER COMPANIES, INC. AND SUBSIDIARIES GAAP to Non-GAAP Reconciliation Constant Currency Revenue Growth and Organic Revenue Growth Net Sales
What we know about the Jeju Air plane crash in South KoreaMHSA executive board takes action on realignment for football
Former officials urge closed-door Senate hearings on Tulsi Gabbard, Trump's pick for intel chief
Copy link Copied Copy link Copied Subscribe to gift this article Gift 5 articles to anyone you choose each month when you subscribe. Already a subscriber? Login Dwindling buyer demand and a glut of stock have prompted more than half of all Sydney home sellers to strike a deal ahead before auction rather than risk not finding a buyer, data from CoreLogic shows. The waning seller confidence comes as the spring auction market failed to ignite a rebound in buyer activity amid high interest rates and declining affordability. Copy link Copied Copy link Copied Subscribe to gift this article Gift 5 articles to anyone you choose each month when you subscribe. Already a subscriber? Login Introducing your Newsfeed Follow the topics, people and companies that matter to you. Latest In Residential Fetching latest articles Most Viewed In Property